Ethic Inc. Buys 22,001 Shares of Sanofi (NASDAQ:SNY)

Ethic Inc. lifted its stake in shares of Sanofi (NASDAQ:SNY) by 26.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 105,127 shares of the company’s stock after acquiring an additional 22,001 shares during the quarter. Ethic Inc.’s holdings in Sanofi were worth $5,070,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Synergy Asset Management LLC purchased a new position in shares of Sanofi in the 4th quarter valued at $25,000. McClarren Financial Advisors Inc. boosted its holdings in shares of Sanofi by 952.6% in the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after buying an additional 543 shares in the last quarter. Lee Danner & Bass Inc. purchased a new position in shares of Sanofi in the 4th quarter worth approximately $31,000. Bessemer Group Inc. raised its stake in shares of Sanofi by 59.8% during the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company’s stock worth $32,000 after acquiring an additional 242 shares in the last quarter. Finally, Sierra Ocean LLC purchased a new stake in Sanofi during the fourth quarter valued at approximately $44,000. Institutional investors own 14.04% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on SNY shares. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. BNP Paribas started coverage on Sanofi in a report on Tuesday, April 15th. They issued an “outperform” rating and a $65.00 price target for the company. Hsbc Global Res upgraded shares of Sanofi to a “strong-buy” rating in a report on Monday, April 28th. The Goldman Sachs Group assumed coverage on shares of Sanofi in a research report on Friday, March 21st. They issued a “neutral” rating and a $65.00 price objective for the company. Finally, Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $63.33.

Sanofi Trading Down 4.1 %

Shares of NASDAQ:SNY opened at $49.98 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. Sanofi has a 52-week low of $45.80 and a 52-week high of $60.12. The stock has a market cap of $126.26 billion, a price-to-earnings ratio of 20.07, a PEG ratio of 1.01 and a beta of 0.55. The business has a 50-day moving average price of $54.22 and a 200-day moving average price of $52.00.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.90 by $0.04. The business had revenue of $10.41 billion during the quarter, compared to analysts’ expectations of $9.79 billion. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The business’s quarterly revenue was down 11.0% compared to the same quarter last year. During the same period in the previous year, the business posted $1.78 EPS. Equities analysts predict that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be paid a dividend of $2.0369 per share. The ex-dividend date is Friday, May 9th. This represents a dividend yield of 3.1%. This is a positive change from Sanofi’s previous annual dividend of $1.48. Sanofi’s dividend payout ratio (DPR) is presently 57.14%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.